Roger Jeffs - Mar 14, 2024 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Herriot Tabuteau, M.D., Attorney-in-Fact
Stock symbol
AXSM
Transactions as of
Mar 14, 2024
Transactions value $
-$1,467,463
Form type
4
Date filed
3/15/2024, 08:05 PM
Previous filing
Feb 29, 2024
Next filing
Mar 19, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -13K -100% $0.00* 0 Mar 14, 2024 Common Stock 13K $22.03 Direct F1, F2
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -17K -100% $0.00* 0 Mar 14, 2024 Common Stock 17K $25.53 Direct F1, F2
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -2.35K -100% $0.00* 0 Mar 15, 2024 Common Stock 2.35K $29.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents an exercise of stock options.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4 Represents additional shares held indirectly by the Reporting Person prior to March 14, 2023.